(Abstracted from Fertil Steril 2019;112:82–88)
Blastocyst biopsy as a means of preimplantation genetic testing (PGT) continues to increase in popularity and might provide a greater number of viable cells per biopsy compared with cleavage-stage biopsy. The increased number of testable cells enables the application of comprehensive chromosome screening modalities including next-generation sequencing, as well as the combination of multiple genetic tests.
Institute of Reproduction and Stem Cell Engineering, Basic Medical College, Central South University (H.H., S.J., C.F.L., Y.Q.T., K.L.L., S.P.Z., F.G., G.X.L., G.L.); Key Laboratory of Stem Cell and Reproductive Engineering, Ministry of Health (C.F.L., Y.Q.T., G.X.L., G.L.); and Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, People's Republic of China (C.F.L., Y.Q.T., K.L.L., S.P.Z., F.G., G.X.L., G.L.)